Eric E. Poma - 23 Jan 2024 Form 4 Insider Report for Molecular Templates, Inc.

Reporting relationship: Chief Executive Officer and Chief Scientific Officer, Director
Issuer ticker: N/A
Reported as of: 23 Jan 2024
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Jan 2024, 17:32:39 UTC
Prior SEC filing: 17 Feb 2023
Next SEC filing: 25 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Eric E. Poma

Key filing fact

Eric E. Poma filed Form 4 for Molecular Templates, Inc. on 25 Jan 2024.

Key facts

This page summarizes Eric E. Poma's Form 4 filing for Molecular Templates, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 25 Jan 2024, 17:32.

Change

Previous filing in this sequence was filed on 17 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MTEM transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +23,333
Change %
Price: $0.000000
Shares after: 23,333
Date: 23 Jan 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 23,333
Exercise price: $3.55
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The figures reflected herein have been adjusted to take into account a 1 for 15 reverse split of the Company's common stock that was effected on August 11, 2023.

Footnote F2

25% of the total number of shares subject to the option shall vest on January 23, 2025, and the remaining 75% shall vest in thirty-six (36) equal monthly installments, subject to the reporting person's continued service through the applicable vesting dates.

SEC remarks

Chief Executive Officer and Chief Scientific Officer